Volume 7, Issue 4 (2022)
SJMR 2022, 7(4): 231-241 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Mohammadian H, Nateghi M R. The Human Papillomavirus (HPV) and Its Vaccines: A Narrative Review. SJMR 2022; 7 (4) : 5
URL: http://saremjrm.com/article-1-282-en.html
URL: http://saremjrm.com/article-1-282-en.html
1- Sarem Gynecology, Obstetrics and Infertility Research Center, Sarem Women's Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran
Abstract: (2479 Views)
Human Papillomavirus (HPV) is a virus that is transmitted mainly during sex and through direct contact with people's skin. This virus belongs to a large family of viruses and is the most common sexually transmitted infection. Unfortunately, most people infected with this virus are unaware of this issue, since various serotypes of this virus are involved in causing precancerous lesions and cancer, especially cervical cancer; it is essential to know more about it. In most parts of the world, this cancer is the second or third most common cancer in women. Due to the relative prevalence of this virus in recent years, many studies have been conducted in the field of its prevention during the last few decades, which has led to the production of various types of vaccines and their introduction to the market. The present review study was conducted to introduce the types of this virus, their pathogenicity, ways to prevent it, and the details of the vaccines available in the Iranian Pharmacopoeia. It is hoped that by vaccinating the women and girls of the target group, we will see a decrease in the spread of this virus and, consequently, a reduction in its harmful effects on the general health of society. It even seems that if a national vaccination program is implemented in the target group, it is possible to eradicate cervical cancer in the coming decades.
Article number: 5
Keywords: Human Papillomavirus (HPV), Genital Wart, Cancer of Cervix, Prevention, Vaccination, Gardasil Vaccine, Cervarix Vaccine, Papilloguard Vaccine.
Article Type: Systematical Review |
Subject:
Health and safety
Received: 2022/12/26 | Accepted: 2023/01/26 | Published: 2023/08/29
Received: 2022/12/26 | Accepted: 2023/01/26 | Published: 2023/08/29
References
1. Announcement the Society of Gynecologic Oncologists. Statement on a cervix cancer vaccine. Gynecol Oncol 2006; 101. [DOI:10.1016/j.ygyno.2006.04.013]
2. Behtash N, Ghaemmaghami F, Yarandi F, Ardalan FA, Khanafshar N. Cutaneous metastasis from carcinoma of the cervix at the drain site. Gynecol Oncol 2002; 85: 209- 11. [DOI:10.1006/gyno.2001.6559]
3. Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(RR-05):1-30.
4. Bzhalava D. Human papillomavirus reference clones. International Human Papillomavirus Reference Center. Available at: URL: http://www.hpvcenter.se/html/refclones.html, consulté en septembre; 2014.
5. Behtash N, Mousavi A, Mohit M, Modares M, Khanafshar N, Hanjani P. Simple hysterectomy in the presence of invasive cervical cancer in Iran. Int J Gynecol Cancer 2003; 13: 177-81. [DOI:10.1136/ijgc-00009577-200303000-00013]
6. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papilloma virus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31: 14-19. [DOI:10.1093/oxfordjournals.jncimonographs.a003476]
7. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89(43):465- 91.
8. Safaei A, Khanlari M, Momtahen M, Monabati A, Robati M, Amooei S, et al. Prevalence of high-risk human papillomavirus types 16 and 18 in healthy women with cytologically negative pap smear in Iran. Indian J Pathol Microbiol 2010; 53(4):681-5. [DOI:10.4103/0377-4929.72030]
9. Shahramian I, Heidari Z, Mahmoudzadeh-Sagheb H, Moradi A, Forghani F. Prevalence of HPV infection and high risk HPV genotypes (16, 18), among monogamous and polygamous women, in Zabol, Iran. Iran J Public Health 2011; 40(3):113-21.
10. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012; 100(Pt B):1-441.
11. 11 Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348: 489-90. [DOI:10.1056/NEJMoa021641]
12. Castellsague X, Diaz M, De Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst 2006; 98: 303-15. [DOI:10.1093/jnci/djj067]
13. Daling JR, Madeleine MM, Johnson LG, Schwartz SM, Shera KA, Wurscher MA, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101: 270-80. [DOI:10.1002/cncr.20365]
14. Schiffman M, Kjaer SK. Chapter 2: Natural history of anogenital human papilloma virus infection and neoplasia. J Natl Cancer Inst Monogr 2003; 31: 14-19. [DOI:10.1093/oxfordjournals.jncimonographs.a003476]
15. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics 2006; CA Cancer J Clin 2006; 56: 106-30. [DOI:10.3322/canjclin.56.2.106]
16. Freeman HP, Wingrove BK. Excess cervical cancer mortality: a marker for low access to health care in poor communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities 2005; No. 05-5282.
17. Behbakht K, Lynch A, Teal S, Degeest K, Massad S. Social and cultural barriers to Papanicolaou test screening in an urban population. Obstet Gynecol 2004; 104: 1355-61. [DOI:10.1097/01.AOG.0000143881.53058.81]
18. Cooper CP, Saraiya M, McLean TA, et al. Report from the CDC. Pap test intervals used by physicians serving low-income women through the National Breast and Cervical Cancer Early Detection Program. J Womens Health 2005; 14: 670-8. [DOI:10.1089/jwh.2005.14.670]
19. Hoyo C, Yarnall KS, Skinner CS, Moorman PG, Sellers D, Reid L. Pain predicts nonadherence to pap smear screening among middle-aged African American women. Prev Med 2005; 41: 439-45. [DOI:10.1016/j.ypmed.2004.11.021]
20. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325: 572-6. [DOI:10.1136/bmj.325.7364.572]
21. Khan MJ, Castle PE, Lorincz AT, Wacholder S, Sherman M, Scott DR, Rush BB, Glass AG, Schiffman M. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9. [DOI:10.1093/jnci/dji187]
22. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005; 97: 1066- 71. [DOI:10.1093/jnci/dji186]
23. Einstein MH, Cruz Y, El-Awady MK, Popescu NC, DiPaolo JA, van Ranst M, et al. Utilization of the human genome sequence localizes human papillomavirus type 16 DNA integrated into the TNFAIP2 gene in a fatal cervical cancer from a 39-year-old woman. Clinn Cancer Res 2002; 8: 549- 54.
24. Wang SS, Sherman ME, Hildesheim A, Lacey JV, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer 2004; 100: 1035- 44. [DOI:10.1002/cncr.20064]
25. 25 Kyndi M, Frederiksen K, Kruger-Kjaer S. Cervical cancer incidence in Denmark over six decades (1994-2000). Acta Obstet Gynecol Scand 2006; 85: 106-11. [DOI:10.1080/00016340500324423]
26. 26. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 1247-55. [DOI:10.1016/S0140-6736(06)68439-0]
27. 27. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillomaviurs-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006; 107: 18- 27. Erratum in: Obstet Gynecol 2006; 107: 1425. [DOI:10.1097/01.AOG.0000192397.41191.fb]
28. 28. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6: 271-8. [DOI:10.1016/S1470-2045(05)70101-7]
29. 29. Frisch M, Biggar RJ, Goedert JJ. Human Papillomavirusassociated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92: 1500-10. [DOI:10.1093/jnci/92.18.1500]
30. 30. Petca A, Borislavschi A, Zvanca ME, Petca RC, Sandru F, Dumitrascu MC. Non-sexual HPV transmission and role of vaccination for a better future (Review). Exp Ther Med. 2020 Dec; 20(6):186. doi: 10.3892/etm.2020.9316. Epub 2020 Oct 13. PMID: 33101476; PMCID: PMC7579832. [DOI:10.3892/etm.2020.9316]
31. عمادیان ساروی سیدامید ، نقشوار فرشاد ، رفیعی علیرضا ، ملکی ایرج ، ترابی زاده ژیلا ، رضایی فر محمد. ارتباط عفونت پاپیلوما ویروس انسانی با کارسینوم سلول سنگفرشی مری، نشریه: مجله علمی پژوهشی دانشگاه علوم پزشکی بابل، سال:1390، دوره:13، شماره:4 (پی در پی 61)، صفحات :54-59.
32. 32. National Center for Health Statistics, Charles J. Rothwell, M.S., M.B.A., Director
33. Jennifer H. Madans, Ph.D., Associate Director for Science/Division of Health and Nutrition Examination Surveys/Kathryn S. Porter, M.D., M.S., Director Ryne Paulose-Ram, Ph.D., Associate Director for Science/Page last reviewed: April 6, 2017/Content source: CDC/National Center for Health Statistics.
34. .محمود پناهی. پاپیلوما ویروسها، HIV-1 و سیفیلیس، مجله دانشکده پزشکی دانشگاه علوم پزشکی مشهد، دوره 51، شماره 2، صفحه 136-133، 1387.
35. نادره بهتاش، مژگان کریمی زارچی. مقاله مروری سرطان سرویکس، نقش واکسن HPV در پیشگیری، مجله دانشکده پزشکی، دانشگاه علوم پزشکی تهران، دوره ٦٤ ، شماره ١٢، اسفند ١٣٨٥، ٨-1.
36. ملیحه حسن زاده مفرد، لیدا جدی، شهناز احمدی. نقش واکسن HPV در پیشگیری از سرطان دهانه رحم، مقاله مروری، مجله زنان، مامایی و نازایی ایران، دوره 19، شماره 21، صفحه 29-22.
37. 36. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30(Suppl 5):P55-70. [DOI:10.1016/j.vaccine.2012.06.083]
38. 37. Elissa Meites, Julianne Gee, Elizabeth Unger, Lauri Markowitz. Human Papillomavirus, Pink Book, 14th Edition ,August 2021.
39. 38. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006; 24(Suppl 3):S3/35-41. [DOI:10.1016/j.vaccine.2006.06.015]
40. https://www.cdc.gov/condomeffectiveness/latex.html
41. http://noyanbiopharma.co/vaccine
42. https://www.clinicneo.com
43. https://www.sciencephoto.com
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
